Copenhagen, 2013-02-11 12:37 CET (GLOBE NEWSWIRE) -- Pursuant to the Danish Securities Trading Act, section 28a, Zealand Pharma A/S shall announce transactions in the company’s shares and related securities by executives and persons/companies closely related to them. In this regard, Zealand Pharma announces the following transactions: Name: Agneta Svedberg Reason: Senior Vice President and Chief Operating Officer Issuer: Zealand Pharma A/S Type Warrants ISIN code: DK0060257814 Transaction: Allocation Trading date: 8 February 2013 Market: NASDAQ OMX København A/S Amount (number of warrants): 67,012 Exercise Price: DKK 87.45 Hereafter, Agneta Svedberg owns 67,012 warrants and 0 shares in Zealand Pharma A/S. Name: Christian Thorkildsen Reason: Employee elected Board member Issuer: Zealand Pharma A/S Type Warrants ISIN code: DK0060257814 Transaction: Allocation Trading date: 8 February 2013 Market: NASDAQ OMX København A/S Amount (number of warrants): 13,500 Exercise Price: DKK 87.45 Hereafter, Christian Thorkildsen owns 54,000 warrants and 23,329 shares in Zealand Pharma A/S. Name: Hanne H. Bak Reason: Employee elected Board member Issuer: Zealand Pharma A/S Type Warrants ISIN code: DK0060257814 Transaction: Allocation Trading date: 8 February 2013 Market: NASDAQ OMX København A/S Amount (number of warrants): 13,500 Exercise Price: DKK 87.45 Hereafter, Hanne H. Bak owns 54,000 warrants and 20,109shares in Zealand Pharma A/S. ? Name: Helle Størum Reason: Employee elected Board member Issuer: Zealand Pharma A/S Type Warrants ISIN code: DK0060257814 Transaction: Allocation Trading date: 8 February 2013 Market: NASDAQ OMX København A/S Amount (number of warrants): 3,750 Exercise Price: DKK 87.45 Hereafter, Helle Størum owns 15,000 warrants and 3,000 shares in Zealand Pharma A/S. ### For further information, please contact: Hanne Leth Hillman, Vice President and Head of IR & Corporate Communication Tel: +45 5060 3689, email: hlh@zealandpharma.com About Zealand Pharma Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand Pharma specializes in the discovery, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company’s focus lies in the field of diabetes/metabolic diseases, and its lead drug invention is lixisenatide (Lyxumia®1), a once-daily GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes. Lyxumia® is approved in Europe (February 2013), and under regulatory review in a large number of other countries globally. In the US, a decision on NDA filing acceptance is expected from the FDA in Q1 2013. Zealand Pharma has a partnering strategy for the development and commercialization of its products and in addition to the collaboration with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Helsinn Healthcare in chemotherapy induced diarrhea and AbbVie in acute kidney injury. Zealand Pharma focuses its activities in disease areas where existing treatments fail to adequately serve patient needs and where the market potential for improved treatments through the use of peptide drugs is high. For further information: www.zealandpharma.com 1. Lyxumia is the protected product name, as the European Medicines Agency (EMA) has approved lixisenatide.